Chinese genomics and molecular diagnostics firm NuProbe has secured $50 million in a Series B round of financing to move forward with its product and team expansion plans in China and the US.
The Series B round was led by its existing shareholder Panlin Capital and a $1-billion joint fund between British-Swedish pharmaceutical giant AstraZeneca and China International Capital Corporation (CICC).